Attorney General Andy Beshear has joined a multistate antitrust lawsuit against the Suboxone makers over allegations the blocked generic competitors and sold the drug at artificially high prices. The suit claims Indivior conspired with Monosol Rx to switch the opioid addiction treatment drug from a tablet to a mouth-dissolving film to prevent or delay generic alternatives to maintain monopoly profits. Beshear called the companies “inhuman” for trying to monopolize the market on the treatment drug, saying the greatest threat to the Commonwealth is substance abuse and “we need every resource available and affordable if we are going to win this battle.” Indivior, formerly Reckitt Benckiser Pharmaceuticals, had exclusivity protection on Suboxone for seven years, using that time frame to create the dissolvable version. Through marketing and price adjustments, the market moved from tablet to film in the U.S. market, despite the company continuing to sell tablets in other countries. The lawsuit accuses Indivior and Monosol of violating the federal Sherman Act, along with state laws, and the 36 attorneys general involved ask the court to stop the companies from engaging in anticompetitive conduct, to restore competition, and to order appropriate relief for consumers and the states, plus costs and fees.